[en] The more widespread use of radioactive isotopes of iodine (collectively referred to as radioiodines) as a research tool, coupled with their diagnostic and therapeutic uses in nuclear medicine, has resulted in an increased number of personnel who are exposed to these radioisotopes and who therefore should be monitored for internal radioiodine contamination. This document describes the minimum acceptable features of a bioassay programme which the Atomic Energy Control Board (AECB) requires to be available in institutions holding a prescribed substance licence authorising the use of significant quantities of ¹²⁵I or ¹³¹I or both. A licensee may submit details of his own proposed bioassay programme to the AECB for approval. If such a programme fails to be approved, the programme described below shall be adhered to. This document does not deal with individuals who are likely to maintain a significant chronic thyroid burden of radioiodine. It is assumed that the radioiodine taken into the body is in a soluble, inorganic form (I₂, iodide or iodate) or in an organic form (e.g. methyl iodide) which is metabolised in the body with a resultant release of iodide. Radioiodinated organic compounds which are not catabolised to iodide in the body to any significant degree are not the subject of this document, since the metabolism of the radioiodine will be dictated by the metabolism of the compound. This means that individuals whose only exposure to radioiodine is in the form of prepared radioiodinated compounds such as antigens and antibodies (e.g. individuals using radio immuno assay kits in which the antigen or antibody is supplied as radioiodinated material) are not required to participate in this bioassay programme for radioiodine